Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan, and Southeast Asia

Incyte and China Medical System Holdings Limited (CMS) announced their collaboration and license agreement for the development and commercialization of povorcitinib, a selective oral JAK1 inhibitor. CMS will receive a license to manufacture povorcitinib in inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, and chronic spontaneous urticaria.